FFUND congratulates O11 biomedical for securing €2.5M from the EIC Accelerator to develop RESPILIQ, a groundbreaking technology designed to treat acute and chronic hypercapnia through the intestine.
About O11 Biomedical GmbH
O11 biomedical is a visionary SME born within BioTex at the RWTH Aachen University that aspires to transform the survival rates and quality of life of patients battling hypercapnia—an affliction characterized by abnormally high CO2 levels in the bloodstream. O11 has developed a minimally invasive, complementary therapeutic approach to hypercapnia to meet the needs of patients and healthcare systems alike: RESPILIQ.
What is the product about?
RESPILIQ offers a solution by utilizing the human intestine as an alternative respiratory organ to effectively lower CO2 levels in the blood. By employing extrapulmonary CO2 elimination via the gut, RESPILIQ allows the lungs to recover without additional damage from aggressive ventilation techniques. It is a user-friendly, minimally invasive, safe and easy-to-administer medical device that can be taken orally or rectally, ensuring good patient compliance in both acute and chronic hypercapnia settings.
The successful completion of the EIC Accelerator project will enable O11 Biomedical to demonstrate clinical evidence of RESPILIQ’s effectiveness and accelerate its path to market.
How did FFUND help?
Filipa Marques, Project Lead: “O11 biomedical’s groundbreaking solution for hypercapnia ticked all the right boxes for securing the EIC Accelerator grant. FFUND played an important role by asking the right questions and guiding the O11 Biomedical team in crafting a proposal that addressed every critical point, leaving no room for doubt about the project’s potential. Commitment from both sides was key to the project’s success!”
Richard Ramaker, CEO and Co-founder of O11 biomedical GmbH: “Filipa’s contribution was not only essential for the success of our proposal, she is also a great person to work with!”
About EIC Accelerator
The EIC Accelerator provides non-dilutive grant funding of up to €2.5 million for innovation development costs, direct equity investments of up to €10 million managed by the EIC Fund for scaling up and other relevant costs, and investments of €10 million to up to €30 million for companies working on technologies of strategic European interest. In addition, EIC-selected companies receive coaching, mentoring, access to investors and corporates, and many other opportunities as part of the EIC community.
